Back to Search Start Over

FMR1 Protein Expression Correlates with Intelligence Quotient in Both Peripheral Blood Mononuclear Cells and Fibroblasts from Individuals with an FMR1 Mutation.

Authors :
Jiraanont P
Zafarullah M
Sulaiman N
Espinal GM
Randol JL
Durbin-Johnson B
Schneider A
Hagerman RJ
Hagerman PJ
Tassone F
Source :
The Journal of molecular diagnostics : JMD [J Mol Diagn] 2024 Jun; Vol. 26 (6), pp. 498-509. Date of Electronic Publication: 2024 Mar 22.
Publication Year :
2024

Abstract

Fragile X syndrome (FXS) is the most common heritable form of intellectual disability and is caused by CGG repeat expansions exceeding 200 (full mutation). Such expansions lead to hypermethylation and transcriptional silencing of the fragile X messenger ribonucleoprotein 1 (FMR1) gene. As a consequence, little or no FMR1 protein (FMRP) is produced; absence of the protein, which normally is responsible for neuronal development and maintenance, causes the syndrome. Previous studies have demonstrated the causal relationship between FMRP levels and cognitive abilities in peripheral blood mononuclear cells (PBMCs) and dermal fibroblast cell lines of patients with FXS. However, it is arguable whether PBMCs or fibroblasts would be the preferred surrogate for measuring molecular markers, particularly FMRP, to represent the cognitive impairment, a core symptom of FXS. To address this concern, CGG repeats, methylation status, FMR1 mRNA, and FMRP levels were measured in both PBMCs and fibroblasts derived from 66 individuals. The findings indicated a strong association between FMR1 mRNA expression levels and CGG repeat numbers in PBMCs of premutation males after correcting for methylation status. Moreover, FMRP expression levels from both PBMCs and fibroblasts of male participants with a hypermethylated full mutation and with mosaicism demonstrated significant association between the intelligence quotient levels and FMRP levels, suggesting that PBMCs may be preferable for FXS clinical studies, because of their greater accessibility.<br />Competing Interests: Disclosure Statement R.J.H. and F.T. received funding from the Azrieli Foundation and Zynerba Pharmaceuticals to perform treatment studies in fragile X syndrome.<br /> (Copyright © 2024 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1943-7811
Volume :
26
Issue :
6
Database :
MEDLINE
Journal :
The Journal of molecular diagnostics : JMD
Publication Type :
Academic Journal
Accession number :
38522837
Full Text :
https://doi.org/10.1016/j.jmoldx.2024.02.007